Alimera Sciences (NASDAQ: ALIM) is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The company is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s product and development portfolio are designed to treat early- and late-stage diseases. For more information, visit the company’s website at  www.alimerasciences.com